These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30972807)

  • 1. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.
    Nicoll AJ; Roberts SK; Lim R; Mitchell J; Weltman M; George J; Wigg A; Stuart K; Gow P; MacQuillan G; Tse E; Levy M; Sood S; Zekry A; Cheng W; Mitchell J; Skoien R; Sievert W; Strasser SI; McCaughan GW;
    Aliment Pharmacol Ther; 2019 May; 49(10):1314-1322. PubMed ID: 30972807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score.
    De Martin E; Coilly A; Chazouillères O; Roux O; Peron JM; Houssel-Debry P; Artru F; Silvain C; Ollivier-Hourmand I; Duvoux C; Heurgue A; Barge S; Ganne-Carrié N; Pageaux GP; Besch C; Bourlière M; Fontaine H; de Ledinghen V; Dumortier J; Conti F; Radenne S; Debette-Gratien M; Goria O; Durand F; Potier P; Di Martino V; Reboux N; Ichai P; Sebagh M; Mathurin P; Agostini H; Samuel D; Duclos-Vallée JC;
    J Hepatol; 2021 Jun; 74(6):1325-1334. PubMed ID: 33503489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
    Czaja AJ; Carpenter HA
    J Clin Gastroenterol; 2005 Oct; 39(9):819-25. PubMed ID: 16145346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
    Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
    Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
    Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
    Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
    Liberal R; Gaspar R; Lopes S; Macedo G
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine.
    Giannakopoulos G; Verbaan H; Friis-Liby IL; Sangfelt P; Nyhlin N; Almer S;
    Dig Liver Dis; 2019 Feb; 51(2):253-257. PubMed ID: 30389427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use.
    Ytting H; Larsen FS
    Scand J Gastroenterol; 2015 Aug; 50(8):1025-31. PubMed ID: 25862144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
    Fallatah HI; Akbar HO
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy.
    Sharzehi K; Huang MA; Schreibman IR; Brown KA
    Can J Gastroenterol; 2010 Oct; 24(10):588-92. PubMed ID: 21037986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Autoimmune Hepatitis.
    Goel A; Kwo P
    Clin Liver Dis; 2024 Feb; 28(1):51-61. PubMed ID: 37945162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of poor response to therapy in Autoimmune Hepatitis.
    Muratori P; Lalanne C; Bianchi G; Lenzi M; Muratori L
    Dig Liver Dis; 2016 Sep; 48(9):1078-81. PubMed ID: 27378707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
    Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
    Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A national retrospective study of paediatric end-stage liver disease as a predictor of change to second-line therapy in children with autoimmune hepatitis.
    Zizzo AN; Jimenez-Rivera C; Kim J; Schreiber RA; Ling SC; Yap J; Critch J; Ahmed N; Alvarez F; Kamath BM;
    Liver Int; 2017 Oct; 37(10):1562-1570. PubMed ID: 28199778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.